Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) CFO Latha Vairavan sold 2,853 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $25.18, for a total transaction of $71,838.54. Following the transaction, the chief financial officer owned 87,754 shares in the company, valued at approximately $2,209,645.72. The trade was a 3.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Latha Vairavan also recently made the following trade(s):
- On Monday, February 2nd, Latha Vairavan sold 1,320 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.50, for a total value of $33,660.00.
Arcutis Biotherapeutics Price Performance
Shares of NASDAQ ARQT opened at $23.60 on Wednesday. The business has a fifty day moving average price of $27.02 and a two-hundred day moving average price of $24.03. The stock has a market capitalization of $2.93 billion, a PE ratio of -168.56 and a beta of 1.66. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.17 and a quick ratio of 2.99. Arcutis Biotherapeutics, Inc. has a fifty-two week low of $11.86 and a fifty-two week high of $31.77.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The company had revenue of $129.50 million for the quarter, compared to analysts' expectations of $110.79 million. As a group, equities analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Arcutis Biotherapeutics
Hedge funds have recently modified their holdings of the business. Perpetual Ltd increased its holdings in Arcutis Biotherapeutics by 7,534.3% in the third quarter. Perpetual Ltd now owns 2,024,606 shares of the company's stock valued at $38,164,000 after purchasing an additional 1,998,086 shares during the period. Suvretta Capital Management LLC lifted its stake in shares of Arcutis Biotherapeutics by 14.2% in the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company's stock worth $347,435,000 after acquiring an additional 1,486,000 shares during the period. Jennison Associates LLC boosted its holdings in Arcutis Biotherapeutics by 10.3% in the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company's stock valued at $230,990,000 after acquiring an additional 1,144,714 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in Arcutis Biotherapeutics by 12.4% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 9,874,511 shares of the company's stock worth $138,441,000 after purchasing an additional 1,089,227 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Arcutis Biotherapeutics by 1,228.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company's stock valued at $33,872,000 after purchasing an additional 1,078,546 shares during the last quarter.
Wall Street Analyst Weigh In
A number of research firms have recently commented on ARQT. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a report on Monday, December 29th. Mizuho reduced their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday. Zacks Research downgraded shares of Arcutis Biotherapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 29th. Guggenheim boosted their target price on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Finally, Needham & Company LLC boosted their price objective on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.86.
Check Out Our Latest Analysis on ARQT
Key Headlines Impacting Arcutis Biotherapeutics
Here are the key news stories impacting Arcutis Biotherapeutics this week:
- Positive Sentiment: Pipeline update — Arcutis enrolled the first participant in a Phase 1a/1b study of ARQ‑234 (a CD200R agonist) to assess safety/tolerability in healthy volunteers and adults with moderate‑to‑severe atopic dermatitis. This is a clear development catalyst supporting longer‑term growth potential. Read More.
- Neutral Sentiment: Broker update — Mizuho trimmed its price target (reported moves show PT cut from $37 to $35) but retained an Outperform stance; that lowers near‑term upside while keeping analyst conviction intact. Read More.
- Neutral Sentiment: Fund filings — Baron Health Care Fund published Q4 activity (no clear large position change in ARQT reported), so fund flows aren’t a decisive driver based on available filings. Read More.
- Neutral Sentiment: Short‑interest reporting in the feeds is inconsistent/erroneous (reports show 0 shares / NaN changes) and provides no reliable signal; treat those numbers as unreliable until clarified by exchange data.
- Negative Sentiment: Clustered insider selling — Multiple insiders sold shares between Feb 27–Mar 2 (notable filings: Todd Watanabe ~37,349 shares; Masaru Matsuda 8,733 shares plus earlier sales; CFO Latha Vairavan; Patrick Burnett). Aggregated insider dispositions total tens of thousands of shares and are likely weighing on sentiment because clustered sales often trigger investor concern. Representative filings: Watanabe Form 4 Read More., Matsuda Form 4 Read More., MarketBeat roundup Read More.
- Negative Sentiment: Analyst downgrade / negative note — Coverage cited in the newsfeed reports a downgrade and a pessimistic near‑term forecast that corresponded with a sharp intraday drop; that broker action appears to have amplified selling pressure. Read More.
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
